A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

NCT02914275 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2250

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: Seqirus Quadrivalent Inactivated Influenza Vaccine
BIOLOGICAL: Comparator Quadrivalent Inactivated Influenza Vaccine

Sponsor

Seqirus